Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Insilico Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration will leverage Huadong Medicine's advanced innovative drug discovery and screening characterization platform, in combination with Insilico's end-to-end AI-driven drug discovery platform.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
September 08, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Insilico Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Mirvetuximab Soravtansine
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Immunogen
Deal Size : $305.0 million
Deal Type : Collaboration
Details : Partnership accelerates development path for Mirvetuximab in Greater China and expands Huadong Medicine’s oncology portfolio with innovative ADC.
Product Name : Elahere
Product Type : Antibody-drug Conjugate
Upfront Cash : $40.0 million
October 19, 2020
Lead Product(s) : Mirvetuximab Soravtansine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Immunogen
Deal Size : $305.0 million
Deal Type : Collaboration
Reset All
